Important note: Information in this article was accurate in 2008. The state of the art may have changed since the publication date.
Los Angeles Times -- August 4, 2008
Thomas H. Maugh II, Los Angeles Times Staff Writer
The hormone produced good results but would have to be used very carefully to avoid inducing diabetes, said Dr. Steven Grinspoon of the Harvard Medical School, lead author of the paper.
He presented the results, which will be published this week in the Journal of the American Medical Assn., at the International AIDS Conference in Mexico City.
About 40% of males and 16% of females who take cocktails of anti-AIDS drugs for their HIV infections develop fat deposits in the stomach, neck and cheeks. Called visceral fat, it is associated with higher levels of cholesterol and triglycerides and increases the risk of heart attacks and stroke.
Such patients typically have abnormally low levels of growth hormone and researchers had hoped that replacing it with genetically engineered human growth hormone -- the same drug used to treat below-normal growth rates and that is abused in athletics -- might reverse the effects.
But previous studies using higher levels of the hormone produced unacceptable side effects, including tissue swelling and pain in the joints.
Grinspoon and his colleagues studied 56 HIV-positive patients who had deposits of fat in their stomachs and low blood levels of the hormone. Half were given daily doses of about 0.33 milligrams of the hormone, well below the 2 to 4 milligrams used in previous studies. Half the subjects were given a placebo.
Over the 18 months of the study, stomach fat dropped by 8.5% in the patients receiving the hormone, compared to 1.6% in those getting a placebo. The team did not study their cardiovascular risk.
Tests showed some elevation of blood sugar in those receiving the hormone, particularly those who had abnormal glucose tolerance tests at the beginning of the trial. Grinspoon said that future clinical trials should include a diabetes drug, such as metformin, to minimize side effects.
Another study in the special AIDS-themed issue of JAMA found that rifampicin, a drug commonly used to treat tuberculosis, can interfere with treatment for AIDS. The finding was important because about a third of the HIV-positive people in the world also have TB.
Dr. Andrew Boulle and his colleagues at the University of Cape Town in South Africa studied nearly 4,000 people who began HIV treatment between 2001 and 2006. About half received the most commonly used AIDS drug, nevirapine, and the rest received efavirenz -- both of them so-called non-nucleoside reverse transcriptase inhibitors.
About 10% of those in the nevirapine group and about half of those in the efavirenz group also had TB.
At the end of six months, 16.3% of those who received nevirapine when they were already taking rifampicin for TB had treatment failure marked by high levels of HIV in their blood, compared to 8.3% of those who did not have TB.
Rifampicin did not interfere with the efavirenz treatment, however, Boulle told the meeting. It also did not interfere with nevirapine if the patients contracted TB while taking the AIDS drug. The researchers do not know why the drug interferes with HIV treatment.
A third study looked at HIV treatment of injection drug abusers. Some researchers have argued that treatment provides little benefit in this group because they are not motivated to take their AIDS drugs regularly.
Dr. Julio Montaner of the University of British Columbia and his colleagues treated 3,116 patients at Canadian clinics, including 915 who abused drugs.
After an average of five years of treatment, he reported, 26% of the drug abusers had died from all causes, compared to 22% of the other AIDS patients -- a difference that was not statistically significant.
Montaner noted that the drug abusers who were prescribed AIDS drugs were just as likely to use them as those whose infections arose from other sources. But he cautioned that the injection drug abusers are less likely to receive a prescription in the first place, so that their overall death rate will remain higher.
thomas.maugh@latimes.com
080804
LT080802
Copyright © 2008 - Los Angeles Times. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Los Angeles Times, Permissions, Times Mirror Square, Los Angeles, CA 90053. http://www.latimes.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .